Known or suspected alcohol or substance abuse in the preceding 12 months.
Women who are pregnant or breastfeeding.
Women of childbearing potential (WOCP) who are not using at least one method of contraception.
Patients with severe renal impairment (CLcr = 29 mL/min, or eGFR = 29 mL/min/1.73 m2), or moderate or severe hepatic impairment (Child-Pugh classes B or C).
Patients with bladder outlet obstruction (BOO) that, in the opinion of the study urologist, would expose them to risk of urinary retention during treatment with mirabegron.
Patients treated with drugs metabolized by the CYP2D6 pathway.
Patients with supine systolic blood pressure (SBP) = 180 mm Hg, or diastolic blood pressure (DBP) = 110 mm Hg.
Clinically significant, uncontrolled cardiac arrhythmia, unstable angina, congestive heart failure (NYHA Class 3 or 4), or history of myocardial infarction in the preceding 2 years.
History of cancer in the preceding 2 years other than successfully treated, non-metastatic, squamous cell or basal cell carcinoma, or cervical cancer in situ.
Any major urological procedure in the preceding 90 days.
Any major surgical procedure in the preceding 30 days.
Previously treated with mirabegron within 60 days prior to the baseline visit (Visit 2), or previously having failed treatment with mirabegron regardless of duration and timing of treatment.
Current or previous, within the 60 days preceding the baseline visit (Visit 2), treatment with antimuscarinic agents for OAB symptoms; and, willingness to not use antimuscarinic agents for the duration of the study.
Currently receiving any other investigational drug or having received an investigational drug within the 60 days preceding the baseline visit (Visit 2).
Any condition or laboratory test result, which, in the opinion of the Investigator or the Study Urologist, might result in an increased risk to the patient, or would affect their participation in the study.
Any patient who, in the opinion of the Investigator, is not a good candidate for the study or will not be able to follow study procedures.

NCT02536976_exc_T1
Condition
substance abuse
NCT02536976_exc_T2
Condition
alcohol abuse
NCT02536976_exc_T3
Temporal
preceding 12 months
NCT02536976_exc_T4
Scope
alcohol or substance abuse
NCT02536976_exc_T7
Condition
renal impairment
NCT02536976_exc_T8
Qualifier
severe
NCT02536976_exc_T9
Measurement
CLcr
NCT02536976_exc_T10
Value
= 29 mL/min
NCT02536976_exc_T11
Measurement
eGFR
NCT02536976_exc_T12
Value
= 29 mL/min/1.73 m2
NCT02536976_exc_T13
Scope
CLcr = 29 mL/min, or eGFR = 29 mL/min/1.73 m2
NCT02536976_exc_T14
Condition
hepatic impairment
NCT02536976_exc_T15
Qualifier
severe
NCT02536976_exc_T16
Qualifier
moderate
NCT02536976_exc_T17
Scope
moderate or severe
NCT02536976_exc_T18
Measurement
Child-Pugh classes
NCT02536976_exc_T19
Value
B
NCT02536976_exc_T20
Value
C
NCT02536976_exc_T21
Scope
B or C
NCT02536976_exc_T22
Condition
bladder outlet obstruction
NCT02536976_exc_T23
Condition
BOO
NCT02536976_exc_T24
Drug
mirabegron
NCT02536976_exc_T25
Observation
risk of urinary retention
NCT02536976_exc_T27
Measurement
systolic blood pressure
NCT02536976_exc_T28
Qualifier
supine
NCT02536976_exc_T29
Measurement
SBP
NCT02536976_exc_T30
Value
= 180 mm Hg
NCT02536976_exc_T31
Measurement
diastolic blood pressure
NCT02536976_exc_T32
Measurement
DBP
NCT02536976_exc_T33
Value
= 110 mm Hg
NCT02536976_exc_T34
Condition
cardiac arrhythmia
NCT02536976_exc_T35
Qualifier
uncontrolled
NCT02536976_exc_T36
Condition
unstable angina
NCT02536976_exc_T37
Condition
congestive heart failure
NCT02536976_exc_T38
Measurement
NYHA Class
NCT02536976_exc_T39
Value
3
NCT02536976_exc_T40
Value
4
NCT02536976_exc_T41
Scope
3 or 4
NCT02536976_exc_T42
Condition
myocardial infarction
NCT02536976_exc_T43
Temporal
preceding 2 years
NCT02536976_exc_T44
Condition
cancer
NCT02536976_exc_T45
Temporal
preceding 2 years
NCT02536976_exc_T46
Negation
other
NCT02536976_exc_T47
Condition
cervical cancer in situ
NCT02536976_exc_T48
Condition
basal cell carcinoma
NCT02536976_exc_T49
Condition
a, or cer  cell or bas
NCT02536976_exc_T50
Qualifier
non-metastatic
NCT02536976_exc_T51
Scope
squamous cell or basal cell carcinoma, or cervical cancer in situ
NCT02536976_exc_T52
Qualifier
successfully treated
NCT02536976_exc_T53
Procedure
major urological procedure
NCT02536976_exc_T54
Temporal
preceding 90 days
NCT02536976_exc_T55
Procedure
major surgical procedure
NCT02536976_exc_T56
Temporal
preceding 30 days
NCT02536976_exc_T57
Drug
mirabegron
NCT02536976_exc_T58
Temporal
within 60 days prior to the baseline visit
NCT02536976_exc_T59
Reference_point
baseline visit
NCT02536976_exc_T60
Drug
antimuscarinic agents
NCT02536976_exc_T61
Condition
OAB symptoms
NCT02536976_exc_T62
Temporal
within the 60 days preceding the baseline visit
NCT02536976_exc_T63
Reference_point
baseline visit